Volume 22 Issue 7
Jul.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(7): 1158-1161
PENG Ling, CHEN Ying, CHEN Jing. The effect of serum miRNAs on the recurrence of depression in patients with SSRIs withdrawal during consolidation period[J]. Chinese Journal of General Practice, 2024, 22(7): 1158-1161. doi: 10.16766/j.cnki.issn.1674-4152.003589
Citation: PENG Ling, CHEN Ying, CHEN Jing. The effect of serum miRNAs on the recurrence of depression in patients with SSRIs withdrawal during consolidation period[J]. Chinese Journal of General Practice, 2024, 22(7): 1158-1161. doi: 10.16766/j.cnki.issn.1674-4152.003589
shu

The effect of serum miRNAs on the recurrence of depression in patients with SSRIs withdrawal during consolidation period

doi: 10.16766/j.cnki.issn.1674-4152.003589

  • Department of Anxiety Disorders, Shaoxing Seventh People' s Hospital, Shaoxing, Zhejiang 312000, China

Funds:

 2023KY1272

 2022KY056

  • Received Date: 2024-01-09
    Available Online: 2024-09-05
    Abstract
  •   Objective  Based on the theory that microRNA-134 (miR-134) and microRNA-16 (miR-16) are involved in the gene regulation process of depression, this paper analyzes the effects of two factors in serum on the one-year recurrence risk of patients with first-episode depression who stopped taking selective serotonin reuptake inhibitors (SSRIs) during the consolidation period.  Methods  A total of 125 patients with first-episode depression who were treated with 5-hydroxytryptamine reuptake inhibitors and stopped during the consolidation period from October 2021 to May 2022 in Shaoxing Seventh People ' s Hospital were selected. Kaplan-Meier survival analysis and Cox proportional hazard regression model were used to evaluate the effect of serum miR-134 and miR-16 on one-year recurrence after withdrawal.  Results  K-M survival analysis showed that the distribution of the "non-recurrent state" in patients with high serum miR-134 and miR-16 levels was (11.01±0.27) months and (11.14±0.29) months, respectively. This was significantly longer than that in patients with low serum miR-134 [(9.32±0.42) months] and miR-16 [(9.59±0.36) months, with P < 0.05]. Cox analysis showed that family history of depression was the risk factor for one-year recurrence (HR=2.219). The protective factors included prolonged medication time (HR=0.759), elevated serum level of miR-134 (HR=0.005), elevated level of miR-16 (HR < 0.001), and combined physical therapy (HR=0.188).  Conclusion  The expression levels of serum miR-134 and miR-16 have a good preventive and protective effect on the recurrence of first-episode depression patients after stopping SSRIs for one year in consolidation period.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    中华医学会行为医学分会, 中华医学会行为医学分会认知应对治疗学组. 抑郁症治疗与管理的专家推荐意见(2022年)[J]. 中华行为医学与脑科学杂志, 2023, 32(3): 193-202. doi: 10.3760/cma.j.cn371468-20220921-00563

    Chinese Society of Behavioral Medicine; ognitive Coping Therapy Group, Chinese Society of Behavioral Medicine. Expert recommendations on the treatment and management of major depressive disorder(2022)[J]. Chinese Journal of Behavioral Medicine and Brain Science, 2023, 32(3): 193-202. doi: 10.3760/cma.j.cn371468-20220921-00563
    [2]
    陈寿林, 朱生芝, 于畅, 等. 老年抑郁症患者血清指标与认知功能的相关性研究[J]. 中华全科医学, 2022, 20(3): 450-453. doi: 10.16766/j.cnki.issn.1674-4152.002375

    CHEN S L, ZHU S Z, YU C, et al. Correlation between serum indexes and cognitive function in elderly patients with depression[J]. Chinese Journal of General Practice, 2022, 20(3): 450-453. doi: 10.16766/j.cnki.issn.1674-4152.002375
    [3]
    康丽君, 张楠, 王薇, 等. 抑郁症复发与脑功能及结构变化的关系研究进展[J]. 神经损伤与功能重建, 2022, 17(4): 225-227. https://www.cnki.com.cn/Article/CJFDTOTAL-GWKF202204011.htm

    KANG L J, ZHANG N, WANG W, et al. Research progress on the relationship between recurrence of depression and changes of brain function and structure[J]. Neural Injury and Functional Reconstruction, 2022, 17(4): 225-227. https://www.cnki.com.cn/Article/CJFDTOTAL-GWKF202204011.htm
    [4]
    胡园园, 丁研, 林鹏, 等. miRNA-16在常见头颈部恶性肿瘤中的研究进展[J]. 现代肿瘤医学, 2023, 31(6): 1166-1169. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL202306037.htm

    HU Y Y, DING Y, LIN P, et al. The research progress of miRNA-16 in common head and neck tumors[J]. Journal of Modern Oncology, 2023, 31(6): 1166-1169. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL202306037.htm
    [5]
    宋晋, 梁婷, 王强, 等. miR-134/CREB/BDNF通路在低频重复经颅磁刺激影响癫痫大鼠抑郁、焦虑样行为中的作用[J]. 中国老年学杂志, 2022, 42(14): 3562-3565. doi: 10.3969/j.issn.1005-9202.2022.14.052

    SONG J, LIANG T, WANG Q, et al. The role of miR-134/ CREB / BDNF pathway in the effect of low-frequency repetitive transcranial magnetic stimulation on depression and anxiety-like behavior in epileptic rats[J]. Chinese Journal of Gerontology, 2022, 42(14): 3562-3565. doi: 10.3969/j.issn.1005-9202.2022.14.052
    [6]
    顾峰, 周岩, 韦培培. 乳腺癌患者外周血miRNA-134表达及化疗耐药的机制[J]. 重庆医学, 2018, 47(6): 779-782, 785. doi: 10.3969/j.issn.1671-8348.2018.06.018

    GU F, ZHOU Y, WEI P P. Expression of peripheral blood miRNA-134 in patients with breast cancer and mechanism of chemotherapy drug resistance[J]. Chongqing medicine, 2018, 47(6): 779-782, 785. doi: 10.3969/j.issn.1671-8348.2018.06.018
    [7]
    过伟峰, 曹晓岚, 盛蕾, 等. 抑郁症中西医结合诊疗专家共识[J]. 中国中西医结合杂志, 2020, 40(2): 141-148. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202002006.htm

    GUO W F, CAO X L, SHENG L, et al. Expert Consensus on Diagnosis and Treatment of Major Depressive Disorder by Integrated Chinese and Western Medicine[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2020, 40(2): 141-148. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ202002006.htm
    [8]
    高舒展, 张宁. 从临床治愈到临床缓解: 抑郁障碍Remission的认识亟需转变[J]. 临床精神医学杂志, 2022, 32(1): 1-4. doi: 10.3969/j.issn.1005-3220.2022.01.001

    GAO S Z, ZHANG N. From clinical cure to clinical remission: the understanding of remission in major depressive disorder urgently needs to be changed[J]. Journal of Clinical Psychiatry, 2022, 32(1): 1-4. doi: 10.3969/j.issn.1005-3220.2022.01.001
    [9]
    高敏, 高长越. 经颅磁刺激对中枢神经系统胶质细胞的影响及其研究进展[J]. 中华全科医学, 2022, 20(7): 1207-1210, 1239. doi: 10.16766/j.cnki.issn.1674-4152.002559

    GAO M, GAO C Y. Effects and research progress of transcranial magnetic stimulation on glial cells in the central nervous system[J]. Chinese Journal of General Practice, 2022, 20(7): 1207-1210, 1239. doi: 10.16766/j.cnki.issn.1674-4152.002559
    [10]
    尹一淑, 刘军莲, 王佳平, 等. 抑郁症相关发病机制研究进展[J]. 医学综述, 2022, 28(12): 2368-2372. doi: 10.3969/j.issn.1006-2084.2022.12.014

    YIN Y S, LIU J L, WANG J P, et al. Research progress in pathogenesis of depression[J]. Medical Recapitulate, 2022, 28(12): 2368-2372. doi: 10.3969/j.issn.1006-2084.2022.12.014
    [11]
    朱秀芝. miRNA-134调控神经结构可塑性参与抑郁症发病的机制研究[D]. 济南: 山东大学, 2017.

    ZHU X Z. The mechanism of miRNA-134 regulating neural structural plasticity involved in the pathogenesis of depression[D]. Jinan: Shandong University, 2017.
    [12]
    曾志涌, 黄玉玲, 黎云鹏. miRNA-134对缺氧缺血性脑病动物模型的调控作用及机制探讨[J]. 中华神经医学杂志, 2018, 17(9): 925-928.

    ZENG Z Y, HUANG Y L, LI Y P. Regulatory and mechanism of miRNA-134 in animal models of hypoxic ischemic encephalopathy[J]. Chinese Journal of Neuromedicine, 2018, 17(9): 2018, 17(9): 925-928.
    [13]
    胡雅坤, 王志强, 梁家辉. 微小RNA-134靶向调控环腺苷酸应答元件结合蛋白/脑源性神经营养因子通路对脑卒中后抑郁海马神经细胞的影响[J]. 临床神经病学杂志, 2022, 35(1): 56-60. https://www.cnki.com.cn/Article/CJFDTOTAL-LCSJ202201011.htm

    HU Y K, WANG Z Q, LIANG J H. Effect of microRNA-134 targeting cyclic AMP response element binding protein 1/brain derived neurotrophic factor pathway on hippocampal neurons of post-stroke depression[J]. Journal of Clinical Neurology, 2022, 35(1): 56-60. https://www.cnki.com.cn/Article/CJFDTOTAL-LCSJ202201011.htm
    [14]
    郝冉, 王翼鹏, 王永剑, 等. 非编码RNA在抑郁症中的研究进展[J]. 生命科学, 2022, 34(12): 1493-1505. https://www.cnki.com.cn/Article/CJFDTOTAL-SMKX202212004.htm

    HAO R, WANG Y P, WANG Y J, et al. Research progress of non-coding RNA in depression [J]. Chinese Bulletin of Life Sciences, 2022, 34(12): 1493-1505. https://www.cnki.com.cn/Article/CJFDTOTAL-SMKX202212004.htm
    [15]
    钱时兴, 房圆, 孙琳, 等. 西酞普兰对抑郁症患者外周血miRNA-16/5-羟色胺转运体通路的影响[J]. 上海交通大学学报(医学版), 2020, 40(6): 814-819. doi: 10.3969/j.issn.1674-8115.2020.06.017

    QIAN S X, FANG Y, SUN L, et al. Effect of citalopram on miRNA-16/serotonin transporter pathway in peripheral blood of patients with depression[J]. Journal of Shanghai Jiao tong University: Medical Science, 2020, 40(6): 814-819. doi: 10.3969/j.issn.1674-8115.2020.06.017
    [16]
    赵俊, 田会玲, 李昱颉, 等. 电针对抑郁模型大鼠不同脑区miRNA-16及5-羟色胺转运体的影响[J]. 针灸临床杂志, 2019, 35(11): 69-74. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJLC201911018.htm

    ZHAO J, TIAN H L, LI Y J, et al. Effect of electroacupuncture on miRNA-16 and 5-HT transporter in different brain regions of depression model rats[J]. Journal of Clinical Acupuncture and Moxibustion, 2019, 35(11): 69-74. https://www.cnki.com.cn/Article/CJFDTOTAL-ZJLC201911018.htm
    [17]
    查倩倩, 徐莲英, 孔晓明, 等. 老年抑郁症住院患者复发影响因素的回顾性分析[J]. 中国健康心理学杂志, 2022, 30(3): 326-329. https://www.cnki.com.cn/Article/CJFDTOTAL-JKXL202203002.htm

    ZHA Q Q, XU L Y, KONG X M, et al. Influencing factors of relapse in late-life depression[J]. China Journal of Health Psychology, 2022, 30(3): 326-329. https://www.cnki.com.cn/Article/CJFDTOTAL-JKXL202203002.htm
    [18]
    吴婷婷, 娄永翱, 沈翠珍. 老年抑郁症患者复发影响因素分析[J]. 中国医药导报, 2022, 19(29): 77-80. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202229017.htm

    WU T T, LOU Y A, SHEN C Z. Analysis of influencing factors of recurrence in elderly patients with depression[J]. China Medical Herald, 2022, 19(29): 77-80. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202229017.htm
    [19]
    李桂萍, 宋明芬, 李静, 等. 降低脑脊液miR-16的水平对大鼠抑郁样行为的影响[J]. 中国病理生理杂志, 2020, 36(10): 1875-1880. https://www.cnki.com.cn/Article/CJFDTOTAL-ZBLS202010020.htm

    LI G P, SONG M F, LI J, et al. Effects of decreasing miR-16 in cerebrospinal fluid on depression-like behaviors in rats[J]. Chinese Journal of Pathophysiology, 2020, 36(10): 1875-1880. https://www.cnki.com.cn/Article/CJFDTOTAL-ZBLS202010020.htm
    [20]
    马燕妮, 张程程. 精神分裂症、双相情感障碍和抑郁症的跨疾病miRNA分子标记研究进展[J]. 中华医学遗传学杂志, 2022, 39(5): 548-554.

    MA Y N, ZHANG C C. Research progress of cross-disease miRNA molecular markers in schizophrenia, bipolar disorder and depression[J]. Chinese Journal of Medical Genetics, 2022, 39(5): 548-554.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (48) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return